Overall, our results demonstrate potential crosstalk between the status of JAK2/3 mutations and response to JAK2 inhibitors or PD-L1 expression, thus providing a molecular rational for combination of JAK kinase inhibitor therapy and anti-PD1 immunotherapy or combination of JAK inhibition and EGFR targeted TKI therapy in NSCLC patients. Here, JAK2 is linked to non-small cell lung carcinoma.